^
Association details:
| Biomarker: | FGFR mutation + PD-L1 expression |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Balversa (erdafitinib) (FGFR inhibitor, FGFR4 inhibitor, FGFR1 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor) + cetrelimab (JNJ-63723283) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study.
Published date:
05/25/2023
Excerpt:
Pts aged ≥ 18 y with mUC, susceptible FGFRa and measurable disease (no prior systemic therapy for mUC, cis-ineligible) were randomized 1:1 to once-daily ERDA 8 mg (with pharmacodynamically guided uptitration (UpT) to 9 mg) or ERDA 8 mg (no UpT) + IV CET 240 mg...4 pts in each arm were PD-L1 positive. 3/4 (75%) PD-L1 positive pts responded to ERDA+CET vs 0 for ERDA….Combination ERDA+CET demonstrated clinically meaningful activity and was well tolerated.
DOI:
10.1200/JCO.2023.41.16_suppl.4504
Trial ID:
